Canaccord Genuity Maintains Buy on Corcept Therapeutics, Lowers Price Target to $99

Benzinga · 01/02 13:07
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target from $140 to $99.